BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Anthropic Secures $1.5B AI Venture Backed by Wall Street Giants, Shaking Software Sector 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
SAN CARLOS, Calif., May 03, 2018 -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2018 financial and operating results on Thursday, May 10, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.
In order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 2995797. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: https://edge.media-server.com/m6/p/ouykqu6a.
A replay of the call will be available from May 10, 2018 at 7:30 p.m. ET to May 17, 2018 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 2995797. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Evan Smith
FTI Consulting
212-850-5622
[email protected]
